RA Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

RA Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-734,343	Closed	-$60.4M	–	106
2022 Q1	$60.4M	Buy	734,343 +353,297	+93%	+$36.1M	1.32%	21
2021 Q4	$55.9M	Buy	+381,046	New	+$59.2M	0.99%	28
2014 Q2	–	Sell	-656,767	Closed	-$12.5M	–	35
2014 Q1	$12.5M	Hold	656,767	–	–	0.9%	23
2013 Q4	$10.9M	Buy	656,767 +105,044	+19%	+$1.8M	1.27%	20
2013 Q3	$8.36M	Buy	+551,723	New	+$5.42M	0.87%	28

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RA Capital Management's MRTX Position: Q2 2022 in Review

RA Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 734,343 shares — an estimated $60.4M sold.

RA Capital Management first reported a position in MRTX in Q3 2013 and held it in 5 quarters. The position peaked at $60.4M in Q1 2022. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

RA Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
RA Capital Management sold 734,343 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $60.4M.
RA Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2013 and held it in 5 quarters.
RA Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $60.4M in Q1 2022.
230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on RA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.